PROCEPT BioRobotics
RoboScore
59.5
Out of 100. Its robots, plus proof from customers and the press.
All 6 measures have data
News bonus
0.4
From the last 90 days, up to 15
RoboIndex
59.9
Up 0.5 since the 19 Oct ranking
Rank change
No change
Now #6 of 39 in Surgical / Medical · See the board →
Market value
US$1.1B
US$19.83 a share · close 26 Oct 2026
Revenue
US$308M
FY2025
Gross margin
63.7%
FY2025
Cash
US$287M
FY2025
Market value from the end-of-day quote. Revenue, margin and cash from the latest annual report.
Advanced robotic treatments empowering men's health with cutting-edge precision for BPH and prostate care.
Watch PROCEPT BioRobotics robots at work
1 video
Is this your company? Claim it, free. Fix your record, add videos, see who looks.
Claim PROCEPT BioRoboticsMoney and customers
Money raised
Listed · NASDAQ PRCT
Customers
2
2 customers cited in public sources
What the score is made of
How it worksThe score is 65% robots, 30% proof from customers and the press, 5% range of robots. Activity and readiness are shown for context.
Backed by
- Viking Global InvestorsLed Funding round, 2018
Bank / other · United States
2 rounds, led 1 - Perceptive AdvisorsSeries G, 20212 rounds
- CPMGSeries G, 20212 rounds
- T.Rowe Price AssociatesSeries G, 2021
Bank / other
+1 more on record.
From the filings
Annual reports · NASDAQ
| Item | FY2025 | FY2024 | Source |
|---|---|---|---|
| Revenue | US$308M | US$224M | Form 10-K, FY2025 ↗ |
| Revenue growth | +37.2% | Not yet on file | Form 10-K, FY2025 ↗ |
| Gross margin | 63.7% | 61.1% | Form 10-K, FY2025 ↗ |
| R&D spend | US$71.3M | US$62.3M | Form 10-K, FY2025 ↗ |
| Net profit or loss | Loss US$95.6M | Loss US$91.4M | Form 10-K, FY2025 ↗ |
| Cash and equivalents | US$287M | US$334M | Form 10-K, FY2025 ↗ |
| Borrowings | US$51.6M | US$51.5M | Form 10-K, FY2025 ↗ |
| Employees | Not yet on file | Not yet on file |
What the filings do not say
Which customer runs which robot, how many units, and whether it is a pilot or a rollout. That is the deployment record on this page.
Listed peers
Market value at the latest close · 1 week = price change over 7 days
| Company | Listing | Market value | 1 week |
|---|---|---|---|
| Intuitive Surgical | NASDAQ ISRG | US$159.6B | +4.3% |
| Unitree Robotics | SSE STAR 688836 | US$40.7B | +35.5% |
| FANUC | TSE 6954 | US$33.3B | — |
| Horizon Robotics | HKEX 9660 | US$7.8B | −2.3% |
| Yaskawa | TSE 6506 | US$6.6B | — |
| Rainbow Robotics | KOSDAQ 277810 | US$5.1B | — |
FUNDING ROUNDS AND CUSTOMERS BY ROBOT
Bigger dot = bigger round. Hollow = amount not disclosed.
Funding rounds
- Jun 2021Series GUS$85.0MLead not disclosedNot disclosedThe Robot Report ↗
- Feb 2018Not yet on fileUS$118MLed by Viking Global InvestorsThe Robot Report ↗
- Jul 2015Not yet on fileUS$42.0MLead not disclosedNot disclosedMassDevice ↗
Rounds recorded from January 2017. Every amount links to its source.
Suggest an editCustomers
2customers cited
named in public sources · no deployment on file
A deployment is recorded when a public source names both the customer and the robot, or the maker confirms it. Nothing here counts against PROCEPT BioRobotics.
In Surgical / Medical, CMR Surgical, BD Rowa and Catalia Health have deployment evidence on file.
Add a deployment →PROCEPT BioRobotics develops the HYDROS Robotic System, an AI-powered platform for Aquablation therapy to treat benign prostatic hyperplasia (BPH). The system uses real-time ultrasound guidance and a heat-free waterjet for robotic-assisted, heat-free prostate treatment. Hospitals and ambulatory surgery centers in the US and internationally purchase the system. Key differentiators include AI-enabled automation, preservation of sexual function and continence, and efficacy across all prostate shapes and sizes.
Active products
2
Company facts
- HQ
- Redwood City, United States
- Founded
- 2014 · 12 yrs
- Stage
- Listed · NASDAQ PRCT
- Website
- www.procept-biorobotics.com
Active robots by PROCEPT BioRobotics
2 shown| # | Category | ||||
|---|---|---|---|---|---|
| 1 |  | HYDROS Robotic System | Surgical / Medical | Not yet on file | 60.3 |
| 2 | AquaBeam Robotic System | Surgical / Medical | 2017 | 53.0 |
In the news
1 event · last 90 days
+0.4news bonus- Oct 21Did Surgical Robot Adoption Just Shift PROCEPT BioRobotics' (PRCT) Investment Narrative?
In the news
1 event · last 90 days
Why PROCEPT BioRobotics has been in the news, across 1 outlet, collected and classified independently, so a maker cannot add to it. It never changes a robot's RoboScore (the evidence half of the RoboIndex) and it can move a robot up a board by at most 15 points.
Safety reports
We checked the US FDA, NHTSA and OSHA registers. No reports found.
Press coverage
- PROCEPT BioRobotics Announces International Launch of the HYDROS Robotic System
Surgical Robotic Technology · Mar 2024
- St. Luke's Hospital acquires HYDROS Robotic System
Corridor Business · Nov 2023
- First in Ohio to offer HYDROS Robotic System for Aquablation therapy
Central Ohio Urology Group · Sep 2023
Milestones
PROCEPT BioRobotics announces international launch of the HYDROS Robotic System.
St. Luke's Hospital acquires the HYDROS Robotic System for Aquablation therapy.
Series G: raised US$85.0M
Raised US$118M
- 2017launch
Launched AquaBeam Robotic System
Raised US$42.0M
Surgical / Medical buying guides
Industry Knowledge →
Surgical Robot Vendor Selection: Support Coverage, Software Upgrades, and Lifecycle
A surgical robot purchased today will be in your OR for 10–15 years. The support SLA, software upgrade path, end-of-life timeline, and field service model deter…
Pilot to Scale: Case Volume Thresholds for Surgical Robot ROI
Most surgical robot programs break even somewhere between 150 and 400 cases per year depending on platform, procedure mix, and reimbursement. The math is knowab…
Surgeon Training Curve and Proctoring: The 18-Month Onboarding Window
A surgeon's robotic learning curve runs 20–150 cases depending on procedure and prior experience. The proctoring structure, credentialing ladder, and OR efficie…